Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Dec 1;12(11):e231544.
doi: 10.1136/bcr-2019-231544.

Treatment-resistant severe capecitabine-induced diarrhoea resolved with oral budesonide

John Shumar  1 , Zachary Junga  2 , Jeptha T Johnson  3 , Lawrence Goldkind  2
Affiliations
Case Reports

Treatment-resistant severe capecitabine-induced diarrhoea resolved with oral budesonide

John Shumar et al. BMJ Case Rep. .

Abstract

Chemotherapy-induced diarrhoea (CID) is a risk of antineoplastic regimens, often associated with 5-fluorouracil (5-FU), irinotecan and capecitabine. Current treatment guidelines for CID include the use of loperamide and octreotide but do not account for other therapies, including budesonide. Small case reports have shown benefit with budesonide in CID secondary to 5-FU and irinotecan, but there is no literature base addressing budesonide use in CID secondary to capecitabine. We describe a case of a patient with severe capecitabine-induced diarrhoea that was refractory to guideline based therapy but resolved with the use of budesonide.

Keywords: colon cancer; drugs: gastrointestinal system; gastroenterology; gastrointestinal system; pathology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
A medium power view of the colonic mucosa showing mild to moderate active inflammation of the colon demonstrated by expansion of the lamina propria with acute inflammatory cells and focal areas ofcryptitis.
Figure 2
Figure 2
A medium power view of the colonic mucosa showing resolution of the acute inflammation with return of the lamina propria to its normal dimensions. There is no active inflammation present. There is some residual reactive architectural atypia including crypt budding.
See this image and copyright information in PMC

References

    1. Stein A, Voigt W, Jordan K, et al. . Frequency and guideline-based management. Ther Adv Med Oncol 2010;2:51–63. - PMC - PubMed
    1. Miwa M, Ura M, Nishida M, et al. . Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274–81. 10.1016/S0959-8049(98)00058-6 - DOI - PubMed
    1. van Kuilenburg AB, Muller EW, Haasjes J, et al. . Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001;7:1149–53. - PubMed
    1. Maggo G, Grover SC, Grin A. Capecitabine induced colitis. Pathol Res Pract 2014;210:606–8. 10.1016/j.prp.2014.05.005 - DOI - PubMed
    1. Benson AB, Ajani JA, Catalano RB, et al. . Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918–26. 10.1200/JCO.2004.04.132 - DOI - PubMed

Publication types

MeSH terms